AGT and cardiac hypertrophy: To evaluate the impact of miR-25 TuD on cardiac hypertrophy in vivo, we subcutaneously implanted an osmotic minipump for Ang II infusion (3 mg/kg/day) in 8-week-old mice, as illustrated in Figure 2A. To ensure the sustained and long-term inhibition of miR-25, AAV9 miR-25 TuD was systemically delivered via tail vein injection.